Welcome to our dedicated page for Evaxion AS SEC filings (Ticker: EVAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Evaxion A/S filings document a foreign private issuer that furnishes Form 6-K reports for business updates, financial results, clinical and preclinical vaccine-program disclosures, and governance actions. Recent reports describe AI-Immunology™-powered vaccine development, EVX-01 personalized cancer vaccine data in advanced melanoma, platform work in glioblastoma, and infectious disease vaccine design concepts.
The filing record also includes annual general meeting results, approval of the audited annual report, board and auditor elections, leadership-role disclosures, and incorporation of Form 6-K reports by reference into Form S-8, Form F-1, and Form F-3 registration statements. These documents frame Evaxion’s capital-market disclosures around pipeline development, corporate governance, securities registrations, and recurring operating updates.
Evaxion A/S furnished a Form 6-K that provides a company press release titled “Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01.”
The filing states that this report is incorporated by reference into Evaxion’s effective registration statements on Forms S-8, F-3, and F-1, making the press release part of those offerings’ prospectuses to the extent not later superseded.
Evaxion A/S, a Denmark-based clinical-stage TechBio company developing AI-Immunology™ powered vaccines, has filed a Form 6-K for November 2025. The filing furnishes a press release titled “Evaxion announces business update and third quarter 2025 financial results” as Exhibit 99.1 and incorporates this report by reference into multiple existing registration statements on Forms S-8, F-3, and F-1.
Evaxion A/S furnished a Form 6-K announcing a press release titled “Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate.” The company describes itself as a clinical-stage TechBio firm developing AI-Immunology powered vaccines. The press release, dated November 3, 2025, is included as Exhibit 99.1. This report is also incorporated by reference into Evaxion’s existing registration statements on Forms S-8, F-3, and F-1, making the 6-K part of those filings moving forward.
Evaxion A/S (EVAX) filed an amended Form 6-K to correct a prior press release. The amendment confirms the company will announce its business update and third quarter 2025 financial results on November 6, 2025.
The report states the corrected press release is furnished as Exhibit 99.1 and is incorporated by reference into Evaxion’s effective registration statements on Forms S-8, F-3, and F-1. No financial results or guidance are included in this update.
Evaxion A/S (EVAX) filed an amended Form 6-K to correct a prior press release. The amendment confirms the company will announce its business update and third quarter 2025 financial results on November 6, 2025.
The report states the corrected press release is furnished as Exhibit 99.1 and is incorporated by reference into Evaxion’s effective registration statements on Forms S-8, F-3, and F-1. No financial results or guidance are included in this update.
Evaxion A/S filed a Form 6-K and furnished a press release announcing a business update and third quarter 2025 financial results on November 6, 2025. The company describes itself as a clinical-stage TechBio focused on AI-Immunology powered vaccines. The report is incorporated by reference into Evaxion’s registration statements on Form S-8, multiple Form F-1 files, and Form F-3 files as listed.
Evaxion A/S filed a Form 6-K and furnished a press release announcing a business update and third quarter 2025 financial results on November 6, 2025. The company describes itself as a clinical-stage TechBio focused on AI-Immunology powered vaccines. The report is incorporated by reference into Evaxion’s registration statements on Form S-8, multiple Form F-1 files, and Form F-3 files as listed.
Evaxion A/S amended its Articles of Association to reflect multiple warrant exercises and related share capital increases. From October 15–28, 2025, the company registered aggregate share capital increases of nominal DKK 4,735,475, raising its total share capital to nominal DKK 103,783,939.
The warrant exercises brought in aggregate cash consideration of DKK 6,665,343 (or approximately USD 1,038,688 based on the October 28, 2025 exchange rate), comprised of DKK 723,450 (or approximately USD 113,143 based on the October 20, 2025 exchange rate) and USD 925,026. Issuances included 2,025,000 ordinary shares on October 15, 6,479,400 on October 16, 5,350,000 on October 17, and additional tranches through October 28, each with stated nominal increases and cash amounts.
Evaxion A/S furnished a Form 6-K announcing it issued a press release titled “Evaxion raises $7.2 million, extending cash runway to second half of 2027.” The company describes itself as a clinical-stage TechBio business developing AI-Immunology powered vaccines.
The release is included as Exhibit 99.1, and the report is incorporated by reference into Evaxion’s existing registration statements. No additional terms or financing details are provided in this excerpt.
Evaxion A/S reported a leadership change via a Form 6-K. On October 27, 2025, the company issued a press release titled “Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer,” furnished as Exhibit 99.1.
The report is also incorporated by reference into Evaxion’s effective registration statements on Forms S-8, F-1, and F-3, ensuring the press release becomes part of those filings. The submission was signed by Interim Chief Executive Officer Birgitte Rønø.
Evaxion A/S reported share sales and warrant exercises that increased its share capital and updated its Articles of Association. On September 25, 2025, the company sold 1,018,000 American Depositary Shares in an at-the-market offering at an average price of $4.3931 per ADS, generating approximately $4.3 million in proceeds after fees. The related capital increase of nominal DKK 12,725,000 became effective on September 26, 2025, bringing total share capital to nominal DKK 91,682,151.50.
From October 3 to October 10, 2025, warrant exercises led to additional registered share capital increases totaling nominal DKK 7,366,312.5, resulting in aggregate share capital of nominal DKK 99,048,464. These exercises brought in aggregate cash consideration of DKK 10,344,064.35 (approximately USD 1,608,519). The Articles of Association were amended on the relevant dates to reflect these changes and are provided as Exhibit 1.1.
Evaxion A/S furnished a Form 6-K announcing a press release titled “Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01.” The press release, dated October 17, 2025, is provided as Exhibit 99.1.
The report states this Form 6-K is incorporated by reference into Evaxion’s effective registration statements, including Forms S-8, F-3, and F-1. The filing highlights the reported 75% objective response rate for EVX-01 as described in the press release title.